News
Bayer expands women’s health pipeline with KaNDy acquisition
Bayer has announced plans to acquire UK-based biotech company KaNDy Therapeutics, in a move to expand its drug development pipeline in women’s healthcare.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Bayer has announced plans to acquire UK-based biotech company KaNDy Therapeutics, in a move to expand its drug development pipeline in women’s healthcare.